knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 04:59:51 - browse：3445

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： WHO recommends second malaria vaccine

WSS

In early work, researchers turn to CRISPR to treat Alzheimer's

What we owe ALS patients — and why one company fell short

CDC picks Alphabet's Verily for wasterwater surveillance contract

Startup Neumora takes a novel depression drug to Phase 3

Setback for rare diseases as Taysha Gene Therapies pulls back

What we owe ALS patients — and why one company fell short

hotspot

knowledge

explore

Duchenne breakthrough therapy leaves behind pioneering families

What will Novo Nordisk's VC do with its influx of cash?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Study points to new risk in gene therapy death of Terry Horgan

Tori Bowie and the unacceptable rates of Black maternal death

How dance can help nurses traumatized by Covid

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

As digital health tech proliferates, a new institute aims to cut through hype

Walensky prepares to leave CDC — and Congress — behind

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

entertainment

Medicare innovation center doesn’t save money, experts say

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

WHO recommends second malaria vaccine

Medicare has a new plan to address drug shortages

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Sanders adds drug shortage policies to pandemic preparedness bill

leisure time

leisure time

focus

hotspot